Pulmonary circulation represents a vast surface for gas exchange to allow blood to become oxygenated and many circulating substances to be metabolized. Our laboratory studies the modifications of pulmonary circulation in various pathological conditions. These conditions result in increased lung pressure, called pulmonary hypertension, and cause a major reduction in the quality of life and life expectancy of people who suffer from them.
We are studying the diseases that cause pulmonary hypertension to elucidate their mechanisms and find treatments. We are also developing innovative approaches with molecular imaging to detect pulmonary hypertension at an earlier stage. The team members in our laboratory also have expertise in various pre-clinical models of pulmonary hypertension (heart failure, hypoxia, monocrotaline, sugen/hypoxia) and use hemodynamic, molecular biology and histological methods along with cell cultures, isolated pulmonary arteries, isolated lungs and nuclear medicine. We also have expertise in the in vivo study of microcirculatory exchange. We are conducting applied clinical studies and Phase I, Phase II and Phase III human studies.
Our product candidate for the imaging of pulmonary circulation, called PulmoBind, was developed completely at the Montreal Heart Institute and will soon be evaluated in a Phase III study in subjects with pulmonary hypertension. PulmoBind may provide an earlier and more accurate diagnosis of pulmonary hypertension and help doctors treat this disease.
Quang Trinh Nguyen, PhD, Research Associate, Phone: 514-376-3330, extension 3479
Emma Dedelis, TSA, Research Assistant (basic sector), extensions 3477, 3478
Nour Dayeh, Doctoral Student
Nassiba Merabet, PhD, post-doctoral fellow
1) Molecular imaging of pulmonary circulation with PulmoBind
Project is conducted in collaboration with Dr. François Harel (MHI) and Dr. Alain Fournier (INRS-Institut Armand-Frappier) and is, in major part, funded by the Consortium québécois sur la découverte du médicament. Phase I and phase II studies with PulmoBind have been sucessfully completed, and show the product's safety and its unique potential in the diagnosis and follow-up of subjects with pulmonary hypertension. Phase III studies that may lead to the clinical approval of PulmoBind are planned.
2) Study on endothelial cell calcium homeostasis in pulmonary hypertension resulting from left-sided heart failure in mice
Study to elucidate the modifications of endothelial cell calcium homeostasis in pulmonary hypertension associated with left-sided heart failure. In this study, we are using a mouse model that we developed in which pulmonary hypertension is secondary to myocardial infarction induced by ligature of the interventricular coronary artery. In collaboration with Dr. Jonathan Ledoux.
3) Study on the determinants of pulmonary remodelling associated with heart failure
Pulmonary hypertension is associated with major structural remodelling that contributes to shortness of breath in subjects with this condition. We are currently evaluating the effect of new therapeutic classes on pulmonary hypertension and heart failure-related pulmonary remodeling. Animal and human studies are on-going in order to validate the use of these products and to establish a new therapeutic way for heart failure.
Dr Jocelyn Dupuis, MD, PhD
jocelyn.dupuis@bellnet.ca
Team members
Quang Trinh Nguyen, PhD, Research Associate, Phone: 514-376-3330, extension 3479
Emma Dedelis, TSA, Research Assistant (basic sector), extensions 3477, 3478
Nour Dayeh, Doctoral Student
Nassiba Merabet, PhD, post-doctoral fellow
Research projects
1) Molecular imaging of pulmonary circulation with PulmoBind
Project is conducted in collaboration with Dr. François Harel (MHI) and Dr. Alain Fournier (INRS-Institut Armand-Frappier) and is, in major part, funded by the Consortium québécois sur la découverte du médicament. Phase I and phase II studies with PulmoBind have been sucessfully completed, and show the product's safety and its unique potential in the diagnosis and follow-up of subjects with pulmonary hypertension. Phase III studies that may lead to the clinical approval of PulmoBind are planned.
2) Study on endothelial cell calcium homeostasis in pulmonary hypertension resulting from left-sided heart failure in mice
Study to elucidate the modifications of endothelial cell calcium homeostasis in pulmonary hypertension associated with left-sided heart failure. In this study, we are using a mouse model that we developed in which pulmonary hypertension is secondary to myocardial infarction induced by ligature of the interventricular coronary artery. In collaboration with Dr. Jonathan Ledoux.
3) Study on the determinants of pulmonary remodelling associated with heart failure
Pulmonary hypertension is associated with major structural remodelling that contributes to shortness of breath in subjects with this condition. We are currently evaluating the effect of new therapeutic classes on pulmonary hypertension and heart failure-related pulmonary remodeling. Animal and human studies are on-going in order to validate the use of these products and to establish a new therapeutic way for heart failure.
Publications
Links
http://www.labome.org/expert/canada/university/dupuis/jocelyn-dupuis-339...
Contact
Dr Jocelyn Dupuis, MD, PhD
jocelyn.dupuis@bellnet.ca